TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18461894

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX, 2%)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-colistin (CHX-COL, 2%-2%)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 385
Study: 16934640

Group type: EXPERIMENTAL
Intervention: Point-of-care, limited ultrasonography (PLUS)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 262
Study: 12664023

Group type: EXPERIMENTAL
Intervention: Scanned CO(2) laser followed by Q-switched ruby laser (QSRL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Q-switched ruby laser (QSRL) alone
Number of subjects: 13
Study: 10334433

Group type: EXPERIMENTAL
Intervention: Omacor (n-3 fatty acids) 5.1 g/day
Number of subjects: 500

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 500
Study: 8921101

Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone (group B; n = 27)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone (group C; n = 27)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (group A; n = 24)
Number of subjects: 78
Study: 2317426

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia (EA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 32
Study: 759126

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate ointment
Number of subjects: 195

Group type: COMPARATOR
Intervention: Betamethasone dipropionate cream
Number of subjects: 195
Study: 31678935

Group type: EXPERIMENTAL
Intervention: School-based, multi-faceted intervention lasting 9 months, including activities for students, parents, and school environment, supported by a smartphone application.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1200
Study: 26013241

Group type: EXPERIMENTAL
Intervention: Chloramine gel (Perisolv™) applied locally followed by mechanical instrumentation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional non-surgical mechanical debridement
Number of subjects: 18
Study: 25227897

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with fluorouracil and levamisole (5‐FU/Lev)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 380
Study: 24402038

Group type: EXPERIMENTAL
Intervention: Cranberry extract (36 mg proanthocyanidins per day) taken twice daily for 1 year
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo taken twice daily for 1 year
Number of subjects: 171
Study: 22583007

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 65
Study: 18688212

Group type: EXPERIMENTAL
Intervention: Active cannabis (1-8% Delta-9-tetrahydrocannabinol), four times daily for 5 consecutive days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 17550933

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg bid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15837996

Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (day 1: APR 125 mg, OND 8 mg, dexamethasone 12 mg; days 2-3: APR 80 mg qd)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Control regimen (day 1: OND 8 mg, dexamethasone 20 mg; days 2-3: OND 8 mg bid)
Number of subjects: 857
Study: 12623503

Group type: EXPERIMENTAL
Intervention: High-dose polyestradiol phosphate (PEP) 240 mg i.m. twice a month for 2 months and thereafter once a month
Number of subjects: 917

Group type: COMPARATOR
Intervention: Combined androgen deprivation (CAD) with flutamide (Eulexin) 250 mg t.i.d. and triptorelin (Decapeptyl) 3.75 mg per month i.m. or bilateral orchidectomy
Number of subjects: 917
Study: 9864885

Group type: EXPERIMENTAL
Intervention: Copper-bearing IUD (380 mm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copper-bearing IUD (200 mm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copper-bearing IUD (375 mm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copper-bearing IUD (250 mm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-IUD users)
Number of subjects: 0
Study: 7696066

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg orally as premedication
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Induction of anaesthesia with propofol or thiopentone
Number of subjects: 47

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 47
Study: 2966613

Group type: EXPERIMENTAL
Intervention: Maprotiline 75 mg with alcohol (1 g/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxepin 25 mg with alcohol (1 g/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zimeldine 200 mg with alcohol (1 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with alcohol (1 g/kg)
Number of subjects: 12
Study: 29101776

Group type: EXPERIMENTAL
Intervention: Massage by mothers for their premature neonates, 15-minute sessions per day for 5 days.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving no massages.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Massage by mothers for their premature neonates
Number of subjects: 40
Study: 28969615

Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 26289076

Group type: EXPERIMENTAL
Intervention: Dose reduction arm
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard dosing regimen
Number of subjects: 190
Study: 23013236

Group type: COMPARATOR
Intervention: Odanacatib (ODN) 50 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 2-600 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) with high-fat meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) with low-fat meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN)
Number of subjects: 44
Study: 20653672

Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg orally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morphine (30 mg orally)
Number of subjects: 24
Study: 18360018

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1234
Study: 20353023

Group type: EXPERIMENTAL
Intervention: Chinese medicine syndrome-differentiation therapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Pinaverium bromide
Number of subjects: 360
Study: 16270722

Group type: EXPERIMENTAL
Intervention: Pranlukast, 450 mg/day (n = 33)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sustained released Theo, 200 mg/day (n = 34)
Number of subjects: 67
Study: 11445757

Group type: EXPERIMENTAL
Intervention: High-altitude training
Number of subjects: 20
Study: 9482294

Group type: EXPERIMENTAL
Intervention: Chest radiograph
Number of subjects: 522

Group type: COMPARATOR
Intervention: No chest radiograph (Control)
Number of subjects: 522
Study: 7843203

Group type: EXPERIMENTAL
Intervention: Carbamazepine (n = 27)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Phenytoin (n = 8)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Valproate (n = 20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ethosuximide (n = 9)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls (n = 23)
Number of subjects: 59
Study: 3285833

Group type: EXPERIMENTAL
Intervention: 2.5 mg torasemide
Number of subjects: 66

Group type: COMPARATOR
Intervention: 2.5 mg indapamide
Number of subjects: 66
Study: 30762487

Group type: EXPERIMENTAL
Intervention: Single injection of 100 × 10^6 ADMSCs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two injections of 100 × 10^6 ADMSCs at baseline and 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 30
Study: 29855373

Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo (PSAC)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo (SAC)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel (SAC)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel (SAC)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel (SAC)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel (PSAC)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel (PSAC)
Number of subjects: 381
Study: 26889911

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily (n=58)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sulphonylurea (n=52)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 110
Study: 23756717

Group type: EXPERIMENTAL
Intervention: Multimodal treatment (pharmacological and cognitive behavioral therapy)
Number of subjects: 56
Study: 22437554

Group type: EXPERIMENTAL
Intervention: α-tocopherol (50 mg/d) supplementation
Number of subjects: 2112
Study: 18818960

Group type: EXPERIMENTAL
Intervention: Aspirin therapy (best medical management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracranial-extracranial bypass surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved surgical and endovascular techniques
Number of subjects: 0
Study: 17980274

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 351

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 351
Study: 15090799

Group type: EXPERIMENTAL
Intervention: Metformin and exercise training (1 hour of aerobic and resistance training three times a week)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 37
Study: 11805569

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (0.2% paste applied three times a day for eight weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lateral sphincterotomy (surgery)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lateral sphincterotomy
Number of subjects: 65
Study: 9743817

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS, Condrosulf, IBSA, Lugano, CH) 2 x 400 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8092558

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg once daily for 6 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Loratadine and Placebo
Number of subjects: 118
Study: 3396477

Group type: EXPERIMENTAL
Intervention: Cloxacillin plus gentamicin (CX/GM) for 48 hours
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cefotaxime (CTX) for 24 hours
Number of subjects: 124
Study: 29352748

Group type: EXPERIMENTAL
Intervention: Conventional teaching plus the e‐learning program (application on smartphone)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional teaching (control group)
Number of subjects: 62
Study: 27084497

Group type: EXPERIMENTAL
Intervention: Controller-free interactive digital rehabilitation technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 0
Study: 25604912

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation combined with virtual reality training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation combined with virtual reality training
Number of subjects: 20
Study: 23089654

Group type: EXPERIMENTAL
Intervention: No. 3‐0 silk suture
Number of subjects: 30

Group type: COMPARATOR
Intervention: isoamyl 2‐cyanoacrylate glue
Number of subjects: 30
Study: 20508338

Group type: EXPERIMENTAL
Intervention: Calcium and 25-hydroxy vitamin D (25-OHD) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium supplementation only
Number of subjects: 0
Study: 18829995

Group type: EXPERIMENTAL
Intervention: Dedicated bifurcation stents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classic bare-metal stents
Number of subjects: 60
Study: 16826439

Group type: EXPERIMENTAL
Intervention: Single-factor HAQ-DI scoring system
Number of subjects: 569
Study: 12360461

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg daily
Number of subjects: 8076

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 8076

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 8076

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 8076
Study: 10328395

Group type: EXPERIMENTAL
Intervention: Propamidine isethionate 0.1% ophthalmic solution (Brolene) and neomycin-polymyxin B-gramicidin ophthalmic solution (Neotricin)
Number of subjects: 83
Study: 8579031

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2022303

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (30 ml containing 3.8 g EPA and 2.5 g DHA)
Number of subjects: 8
Study: 7100377

Group type: EXPERIMENTAL
Intervention: Motivation at 0c for every .1°F increase in finger temperature
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motivation at 25c for every .1°F increase in finger temperature
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motivation at 50c for every .1°F increase in finger temperature
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Suggestion task difficulty
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: No-suggestion task difficulty
Number of subjects: 47
Study: 31144134

Group type: EXPERIMENTAL
Intervention: Dual-responding-hand condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-responding-hand condition
Number of subjects: 0
Study: 28408010

Group type: EXPERIMENTAL
Intervention: Long-term sequela (LTS) risk mitigation
Number of subjects: 3160

Group type: COMPARATOR
Intervention: HbA1c improvement
Number of subjects: 3160

Group type: EXPERIMENTAL
Intervention: Avoidance of treatment-related heart attack risk
Number of subjects: 3160

Group type: COMPARATOR
Intervention: Control for treatment-related heart attack risk
Number of subjects: 3160
Study: 25995282

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) snack (26 g of protein/6 g of fat per 27 g of carbohydrates)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) snack
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) snack (4 g of protein/12 g of fat per 32 g of carbohydrates)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) snack
Number of subjects: 31

Group type: COMPARATOR
Intervention: No Snack (NoS)
Number of subjects: 31
Study: 24722445

Group type: EXPERIMENTAL
Intervention: 0.75 mg/d atrasentan
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 1.25 mg/d atrasentan
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both doses of atrasentan
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Atrasentan (both doses)
Number of subjects: 211
Study: 22831874

Group type: EXPERIMENTAL
Intervention: Single, oral supplementation of 100,000 IU vitamin D3
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 62
Study: 20297701

Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional drill
Number of subjects: 37
Study: 17524997

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol gel at 1.25 g/day (0.75 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol gel at 2.5 g/day (1.5 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol gel at 5.0 g/day (3 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Estriol 2 mg/day p.o. (control)
Number of subjects: 120
Study: 15545824

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (15 mg/kg) added to the CPB priming solution (Group MP, n = 37)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No methylprednisolone added to the CPB priming (Group NS, n = 37)
Number of subjects: 74
Study: 11350567

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg o.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10204735

Group type: EXPERIMENTAL
Intervention: 50 mg pethidine (P50)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 mg pethidine (P100)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 mg pethidine (P200)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prilocaine + adrenaline (PC)
Number of subjects: 40
Study: 7799085

Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 99mTc‐HMPAO
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DLCO
Number of subjects: 17
Study: 2139843

Group type: EXPERIMENTAL
Intervention: Monophasic LNG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monophasic NET
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triphasic LNG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triphasic GSD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biphasic DSG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monophasic DSG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monophasic CPA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 19-nortestosterone derived progestagens
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 10
Study: 7205145

Group type: EXPERIMENTAL
Intervention: Evaluation method for radioimmunoassay results
Number of subjects: 0
Study: 28983938

Group type: EXPERIMENTAL
Intervention: Moisturizing skincare (bathing every 2 days and using lotion daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Daily bathing without lotion (control)
Number of subjects: 227
Study: 27657522

Group type: EXPERIMENTAL
Intervention: ICS/LABA combination
Number of subjects: 107

Group type: COMPARATOR
Intervention: ICS monotherapy
Number of subjects: 107
Study: 24007699

Group type: EXPERIMENTAL
Intervention: Apathy present
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Apathy present in 73 (7.5%) of 979 older persons without depressive symptoms and cognitive impairment
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Apathy present in 77 (7%) persons with cognitive impairment only
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Apathy present in 51 (5%) depressed persons without cognitive impairment
Number of subjects: 1118
Study: 22411098

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) plus tuition/lecture
Number of subjects: 69

Group type: COMPARATOR
Intervention: Computer-assisted learning (CAL) alone
Number of subjects: 69
Study: 20487077

Group type: EXPERIMENTAL
Intervention: Participants' self-report of fall events
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Fall events reported in participants' case notes
Number of subjects: 153

Group type: COMPARATOR
Intervention: Falls events reported through the hospital reporting systems
Number of subjects: 153

Group type: COMPARATOR
Intervention: Hospital reporting systems
Number of subjects: 153
Study: 17320346

Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panic disorder patients
Number of subjects: 0
Study: 15758763

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 300 mg, 3 times daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14606784

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 10828647

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (copolymer 1)
Number of subjects: 299
Study: 8864316

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg orally)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 28
Study: 1632394

Group type: EXPERIMENTAL
Intervention: Burst overdrive pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autodecremental pacing (10 ms decrement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pacing scheme using a 5 ms coupling decrement
Number of subjects: 0
Study: 6594157

Group type: EXPERIMENTAL
Intervention: Gemeprost vaginal pessaries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extra-amniotic infusion of prostaglandin E2 (PGE2)
Number of subjects: 0
Study: 3514164

Group type: EXPERIMENTAL
Intervention: 40 mg of prednisone daily for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline spirometric data and beta‐agonist responsiveness
Number of subjects: 16

Group type: COMPARATOR
Intervention: Previous studies of corticosteroids in COPD
Number of subjects: 16
Study: 29744972

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 71
Study: 27874299

Group type: EXPERIMENTAL
Intervention: TACO (immersion in 151 L of 2.1°C ± 0.8°C water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON (no immersion)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TACO
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON
Number of subjects: 16
Study: 24780728

Group type: EXPERIMENTAL
Intervention: 100 g dried plum/d
Number of subjects: 160

Group type: COMPARATOR
Intervention: 75 g dried apple/d (comparative control)
Number of subjects: 160